# A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

> **NCT03602495** · PHASE3 · TERMINATED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 204 (actual)

## Conditions studied

- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** Donafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03602495
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-29
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-07-15
- **Target enrollment:** 204 (ACTUAL)
- **Why stopped:** Based on IDMC's recommendations during the interim analysis"the trial has reached the goal of early termination of the trial". the sponsor communicating with CDE, CDE agreed to unblind the trial and submit a NDA.
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602495, "A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03602495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*